ARTL
vs
S&P 500
ARTL
S&P 500
Over the past 12 months, ARTL has underperformed S&P 500, delivering a return of -73% compared to the S&P 500's +14% growth.
Stocks Performance
ARTL vs S&P 500
Performance Gap
ARTL vs S&P 500
Performance By Year
ARTL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Artelo Biosciences Inc
Glance View
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Its programs represent a range of approaches in utilizing the ECS to develop pharmaceuticals for patients with unmet healthcare needs. Its product pipeline includes ART27.13, ART12.11 and ART26.12. ART27.13 is a clinic-ready, potent, peripherally restricted dual synthetic agonist developed for the treatment of cancer-related anorexia and weight loss. ART26.12 is a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), being studied both as a cancer therapeutic and in anxiety-related disorders, including post-traumatic stress disorder (PTSD). ART12.11 is a solid-state composition of cannabidiol (CBD cocrystal) for PTSD and inflammatory bowel diseases.
